Inventiva LEGEND data and prescriber survey highlight lani's potential in MASH
Following the announcement of positive phase 2 (LEGEND) results with lanifibranor + empagliflozin in MASH and T2D, hitting on the primary and multiple secondary endpoints, Inventiva's stock traded down approx. -11%. We believe this response is unjustified given that the results showcase lanifibranor's potential as a combination therapy, further boosting the candidate's positioning in MASH. In addition, Inventiva presented results from payer and prescriber surveys, which we see as further support for lanifibranor's market potential. As such, we continue to believe in lanifibranor and look forward to the last patient first visit in the phase 3 (NATiV3) trial, expected by 1H24. We reiterate our BUY rating and € 10 TP.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.